Marc Beer recently grabbed the headlines after his company, Renovia Inc., participated in a highly acclaimed and anticipated venture capital funding round worth a whopping $42.3 million. Committed to developing groundbreaking diagnostic and therapeutic treatment to patients ailing from pelvic disorders, the company has undoubtedly broken new grounds in securing such a unique form of financing. Accordingly, the capital is expected to empower the company’s clinical trials while also expediting product development for future commercial growth.
Powered by the Perceptive Advisors and Ascension Ventures in conjunction with the Longwood Fund, the Series B Financing brings on board a plethora of influential investors such as Western Technology Investment and Inova Strategic Investment with an eye to redefining pelvic disorder therapy in the U.S and beyond.
Marc Beer Renovia, the company’s CEO and Chairman, recently hailed the immense support generated by this elite group of revolutionaries striving to identify, treat and improve the general health of millions of pelvic disorder patients worldwide. According to him, this remarkable partnership paints a stark picture of the synergetic efforts tailored at integrating healthcare networks and realigning them with the company’s sole vision.
As the CEO, Marc Beer Renovia reiterated the need for harnessing proprietary technologies to optimize digital healthcare provision that will inform patients on new and affordable treatment options tailored at treating pelvic floor disorders. The newly completed funding round speaks volumes about the substantial value generated through innovative diagnostic treatment with a keen emphasis on urinary incontinence.
According to verified reports, urinary incontinence is widely considered to be an adverse medical condition plaguing over 250 million patients worldwide. Renovia Inc has consistently harnessed efforts and pulled all the stops to develop reliable therapy models aimed at improving the lives of affected patients. Since its inception in 2016, the company has made significant strides to create an FDA-approved device that identifies and channels swift movement through the levator plate.
By developing the device, all modern patient-based applications have been enhanced to provide seamless and affordable therapy for debilitated pelvic floor muscles while obtaining crucial data on the patient’s health.
Marc Beer Renovia’s Profile
Marc Beer currently serves as the CEO, Chairman, and Co-Founder at Renovia Inc. With over two decades’ worth of experience, the innovative CEO brings on boards unrivaled expertise in the development and commercialization of diagnostic, pharmaceutical and biotechnology industries. Through his leadership, the company has broken down a multitude of barriers to become a leading healthcare company in the U.S. Marc Beer is an alumnus of Miami University with a Bachelor of Science degree. Learn more: https://www.linkedin.com/in/marcbeer